Agios has reported the first mutant-selective inhibitors of the metabolic enzymes IDH1 and IDH2 and has shown therapeutic effect in preclinical cancer models. The company has a partnership with Foundation Medicine to develop companion diagnostics to identify patients with cancer who have the mutations.